Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 12th, 2020

National Heart Failure Initiative will improve outcomes and quality of life for patients with HF

Initiative supported by founding sponsor Novartis and national sponsor Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.


2020 11 12 14 11 02

By 2030, more than 8 million people in the U.S. are projected to have heart failure, and deaths from HF are the primary cause of the plateau in age-adjusted death rate from CVD overall. In response,  AHA CEO Nancy Brown has announced the AHA’s National Heart Failure Initiative supported by founding sponsor Novartis and national sponsor Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.

The initiative will enhance early identification and optimal treatment of HF, along with patient education, to increase healthy time at home and reduce all-cause mortality by 5%. The extensive expertise and infrastructure of the AHA, scientific partners and industry funders will be leveraged to develop concurrent interventions at several points along the patient care spectrum, including clinical and community touch points, specifically:

  • Establish and support learning health care system using quality improvement infrastructure with real-time feedback for identification of key areas for improvement and evaluation of evidence-based approaches.
  • Develop, implement and evaluate scalable patient empowerment and engagement tools that include personalized technology solutions and facilitate improved access to health care.

The initiative will use established AHA approaches of primary data collection, including the Get With The Guidelines® - HF program, to identify, implement and evaluate processes and develop new standards for HF patient management. Both health care and patient interventions will produce large-scale data collection from in-patient, out-patient and community settings resulting in generation of real-world evidence that will be used for characterization and dissemination of best practices.

Interesting Stories
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
More Content
Health Tech winners
AHA24
AI medical company wins global health tech competition at #AHA24
Nov 20th, 2024
241116 American Heart Association Keynote 0080
AHA24
LBS 08: Advances in lipid therapeutics
Nov 20th, 2024
Crowd shot
AHA24
LBS 07: New approaches to managing AFib
Nov 20th, 2024
Stage shot
AHA24
LBS 06: Medical therapy for heart failure
Nov 20th, 2024
Stage shot
AHA24
LBS 05: Innovation in prevention
Nov 20th, 2024
French Quarter balcony shot
AHA24
Save the date for #AHA25 in New Orleans
Nov 20th, 2024
Asgar headshot
AHA24
Managing patients with symptomatic mitral or tricuspid regurgitation
Nov 18th, 2024
Nancy Brown headshot
AHA24
AHA CEO: Driving breakthroughs
Nov 18th, 2024
Shot of speakers
AHA24
Environmental crises call for more CV research
Nov 18th, 2024
Aha24 Nejm Web Image
AHA24
Streamlining the pathway to publish cardiovascular research
Nov 18th, 2024
Casadei headshot
AHA24
Dissecting the complex relationship between atrial cardiomyopathy and stroke
Nov 18th, 2024
Stage shot
AHA24
LBS 04: Coronary and valvular heart disease
Nov 18th, 2024